Nice work, David. Medivation CEO set for $350M payoff when Pfizer closes its $14B buy

David Hung, Medivation CEO

When Medivation bidders were circling, CEO David Hung fought hard for a higher price for the company’s shareholders. And he was one of them--a big one, as a new securities filing shows.

Hung stands to collect more than $300 million when Pfizer closes on its $14 billion deal for Medivation, thanks to his years of accumulated stock, options, incentive-plan shares and the like.

As of Aug. 18, Hung held 2.84 million stock options, vested and unvested, worth $182 million in the Medivation sale. He owned 1.45 million shares outright, worth another $118.6 million. His incentive-plan share units amounted to 171,528, for a cash value of almost $14 million.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

Then there are Hung’s stock appreciation rights, which, like options, benefit executives when share prices rise. They’re worth $37 million.

His cash severance is peanuts, comparatively--24 months of base salary, or about $1.82 million, according to the company’s securities filing, plus an estimated performance bonus of more than $868,000.

Grand total: About $354 million.

That’s a nice payoff for Hung, who co-founded Medivation in 2003 and spent 13 years building it into a company that could sell for $14 billion. Enough to retire to a private island somewhere, or, more likely, start up another biotech venture.

In the realm of biopharma payouts, it’s hefty. Henri Termeer, who was CEO of Genzyme when Sanofi snapped up his company for $20 billion, bowed out with $158 million in payment for stock, options, performance units and severance benefits.

But if you want to get technical about it, the “golden parachute” part of Hung’s figure is $35.6 million. That amount includes the cash severance and bonus, plus the payoff from unvested options and performance shares, as well as the value of continued health insurance benefits.

Here’s how some other exits compare: David Pyott, CEO of Allergan till Actavis bought the company and assumed its name, was in line for a $100 million goodbye payment along the same lines. Currently Allergan CEO Brent Saunders boasts a $140 million parachute, per Bloomberg’s recent calculations. The cash portion of his severance amounts to $12.2 million alone.

And according to FiercePharma research, Wyeth CEO Bernard Poussot, who also sold his company to Pfizer, exited with $53 million. Schering-Plough’s Fred Hassan, CEO when Merck & Co. pulled off their merger, left with almost $50 million; Schering even covered related taxes, to the tune of $11.7 million.

Special Report: Pharma’s top 5 golden handshakes of the last 5 years

Related Articles:
Allergan chief's $140M-plus golden parachute tops pharma--and most other industries, too
Pfizer plans to shell out a stunning $14B for Medivation. Will the bet pay off?
Actavis' buyout of Allergan could trigger $100M golden parachute for Pyott
Medivation CEO to buyers: You'll pay top dollar for our 'best-in-class' PARP med
Pay up, Sanofi: Tesaro's PARP data give Medivation deal expectations a boost

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.